4-chloro-2-piperidin-1-yl-5-trifluoromethyl-pyrimidine | 847863-19-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-chloro-2-piperidin-1-yl-5-trifluoromethyl-pyrimidine
• 英文别名: Pyrimidine, 4-chloro-2-(1-piperidinyl)-5-(trifluoromethyl)-；4-chloro-2-piperidin-1-yl-5-(trifluoromethyl)pyrimidine
• CAS: 847863-19-8
• 化学式: C₁₀H₁₁ClF₃N₃
• 分子量: 265.666
• InChiKey: HUWAGARMESVAMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  哌啶 、 2,4-二氯-5-三氟甲基嘧啶 在 zinc(II) chloride 、 三乙胺 作用下， 以 乙醚 、 1,2-二氯乙烷 、 叔丁醇 为溶剂， 生成 4-chloro-2-piperidin-1-yl-5-trifluoromethyl-pyrimidine 、
  参考文献：
  名称：

  Selective addition of amines to 5-trifluoromethyl-2,4-dichloropyrimidine induced by Lewis acids

  摘要：

  A variety of 2,4-diamino-pyrimidine systems can be prepared from the corresponding 2,4-dichloropyrimidine by sequential addition of two amines, the first adding selectively to the 4-position. In contrast it was found that 2,4-dichloro-5-trifluoromethyl-pyrimidine yields a 1:1 mixture of the two possible isomers. Lewis acids were employed to increase the ratio of isomers to >10:1 in favor of the 2-addition product. Optimization of the effect of Lewis acid additives on this and other dichloropyrimidine systems will be discussed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.06.025

文献信息

• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：ROTH Gerald Juergen

  公开号：US20120157425A1

  公开（公告）日：2012-06-21

  The invention relates to new piperidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  该发明涉及新的哌啶衍生物，其化学式I，用作药物，用于治疗的方法以及含有它们的药物组合物。
• [EN] PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012001107A1

  公开（公告）日：2012-01-05

  The invention relates to new piperidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及一种新的哌啶衍生物，其化学式为（I），以及它们作为药物的用途，它们的治疗用途的方法以及包含它们的制药组合物。
• PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE
  申请人：Novartis AG

  公开号：EP3514151A1

  公开（公告）日：2019-07-24

  PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

  本研究公开了 PKC 抑制剂。这些 PKC 抑制剂可用于治疗 PKC 相关疾病，包括某些癌症。这些 PKC 抑制剂具有更低剂量下的更佳疗效，可实现肿瘤消退，并具有更好的效力、PK 特性、吸收、胃肠道耐受性和激酶选择性。
• US9006450B2
  申请人：——

  公开号：US9006450B2

  公开（公告）日：2015-04-14